| Literature DB >> 28341828 |
Belinda Wright1, Cali E Willet1,2, Rodrigo Hamede3, Menna Jones3, Katherine Belov1, Claire M Wade4.
Abstract
Devil facial tumour disease (DFTD) has decimated wild populations of Tasmanian devils (Sarcophilus harrisii) due to its ability to avoid immune detection and pass from host to host by biting. A small number of devils have been observed to spontaneously recover from the disease which is otherwise fatal. We have sequenced the genomes of these rare cases and compared them to the genomes of devils who succumbed to the disease. Genome-wide association, based on this limited sampling, highlighted two key genomic regions potentially associated with ability to survive DFTD. Following targeted genotyping in additional samples, both of these loci remain significantly different between cases and controls, with the PAX3 locus retaining significance at the 0.001 level, though genome-wide significance was not achieved. We propose that PAX3 may be involved in a regulatory pathway that influences the slowing of tumour growth and may allow more time for an immune response to be mounted in animals with regressed tumours. This provides an intriguing hypothesis for further research and could provide a novel route of treatment for this devastating disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28341828 PMCID: PMC5428454 DOI: 10.1038/s41598-017-00439-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Summary of loci segregating with DFTD regression identified by GWAS. Key candidate genes for DFTD regression are in bold.
| Scaffold | Scaffold Size (Mb) | No. of SNPs (In top 100) | Best p-value | INDELs | Nearest Candidate Genes |
|---|---|---|---|---|---|
| Chr1_0002 | 1.08 | 97 (2) | 0.00039 | 189 | MKI67 |
| Chr1_0216 | 3.85 | 203 (1) | 0.00094 | 443 | RBL1 |
| Chr1_0248 | 0.97 | 102 (1) | 0.00049 | 217 | CHRNA4 |
| Chr1_0256 | 4.38 | 410 (1) | 0.00094 | 1047 | DOK5 |
| Chr1_0386 | 0.71 | 136 (1) |
| 173 |
|
| Chr2_0233 | 4.02 | 222 (2) | 0.00045 | 562 | YWHAZ |
| Chr2_0238 | 0.81 | 274 (1) | 0.00094 | 411 | EBAG9 |
| Chr2_0398 | 3.39 | 419 (4) | 0.00045 | 945 | UNC13B |
| Chr3_0006 | 0.94 | 14 (1) | 0.00067 | 74 | SEPT2 |
| Chr3_0048 | 2.23 | 96 (1) | 0.00131 | 328 | CD96 |
| Chr3_0369 | 3.06 | 146 (2) | 0.00028 | 451 | STK11IP, INHA, OBSL1 |
| Chr3_0388 | 4.28 | 407 (38) |
| 1496 |
|
| Chr3_0519 | 0.60 | 23 (1) | 0.00028 | 55 | PAX3 (pseudogene) |
| Chr4_0035 | 2.57 | 132 (2) | 0.00028 | 342 | RASAL2, BRINP2 |
| Chr4_0110 | 2.19 | 106 (2) | 0.00094 | 338 | NGFR, PHB |
| Chr5_0005 | 1.75 | 41 (1) | 0.00049 | 146 | CERK |
| Chr5_0006 | 2.48 | 292 (1) | 0.00067 | 636 | FAM19A5 |
| Chr5_0069 | 4.66 | 224 (2) | 0.00131 | 971 | BTBD11 |
| Chr6_0050 | 4.00 | 131 (1) | 0.00094 | 655 | MAPK10, ARHGAP24 |
| Chr6_0079/80 | 0.12 | 12 (0)* | 0.00165 | 69 | SPOCK3 |
| Chr6_0081 | 1.17 | 161 (17) |
| 480 |
|
*Included as scaffolds contains annotations for neighbouring genes of TLL1 (identified by GWAS) and corresponding to a syntenic block as identified by comparison with human, mouse and opossum.
Results from association analysis in targeted SNPs (N = 27) as compared to results obtained from genome-wide association (N = 13).
| Locus | SNP | GWAS | Targeted loci | ||
|---|---|---|---|---|---|
| Chi-square | p-value | Chi-square | p-value | ||
| NBAS | 377874_T | 16.34 | 0.00005*** | 0.9441 | 0.33120 |
| PAX3 | 2290941_C | 13.48 | 0.00024** | 10.94 | 0.00094** |
| PAX3 | 2253019_T | 16.34 | 0.00006*** | 15.48 | 0.00008*** |
| TLL1 | 476140_C | 11.8 | 0.00059** | 5.44 | 0.01968* |
| TLL1 | 635881_C | 11.8 | 0.00059** | 5.347 | 0.02076* |
*Significant at 0.05; **Significant at 0.001; ***Significant at 0.0001.
See Supplementary Material, Table S1 for a full distribution of genotypes for cases and controls.
Details of 11 West Pencil Pine samples used in the genome-wide association study.
| Infection status | Sex | Y.O.B. | Age 1st infected | Diagnostic criteria | Comments |
|---|---|---|---|---|---|
| Regressed | F | 2006 | 5 | Visual inspection | Survived in the wild until age 5 DFTD free |
| Regressed | F | 2006 | 5 | Visual inspection | Survived in the wild until age 6 DFTD free |
| Regressed | F | 2008 | 3 | Histopathology/cytology | Tumour regressed for ~6 months |
| Regressed | F | 2009 | 3 | Visual inspection | Tumour regressed for ~2 years |
| Regressed | F | 2006 | 3 | Histopathology/cytology | Tumour regressed for ~6 months |
| Regressed | M | 2009 | 3 | Cytology | Survived in wild until age 7 DFTD free |
| DFTD-infected | M | 2011 | 18 mths | Histopathology/cytology | Succumbed |
| DFTD-infected | F | 2011 | 15 mths | Histopathology/cytology | Succumbed |
| DFTD-infected | M | 2010 | 18 mths | Histopathology/cytology | Succumbed |
| DFTD-infected | F | 2011 | 18 mths | Histopathology/cytology | Succumbed |
| DFTD-infected | F | 2010 | 15 mths | Histopathology/cytology | Succumbed |
Nb. When a tumour is detected within the mouth on sampling then no biopsy or fine needle aspiration is possible therefore visual inspection scores are used to assign infection status. As sampling took place at 3 month intervals, periods of tumour regression and survival are approximate. Y.O.B. – year of birth. Ages at first infection are given in years except for those given in months (mths).